HDAC9 and hematopoietic and lymphoid cell neoplasm: Previous studies have reported the efficacy of the association of other HDAC inhibitors, such as vorinostat, with ABT‐737 or its orally available derivative ABT‐263, in preclinical models of hematological cancers [41, 42, 43, 44] and solid tumors [45, 46, 47].